Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)
Peter A. Fasching(Comprehensive Cancer Center Erlangen), Michael Untch(Helios Hospital Berlin-Buch)
Cited by 35
Related Papers
Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer
|Journal of Clinical Oncology|2009|151